Q1 Earnings Estimate for uniQure Issued By William Blair

uniQure (NASDAQ:QURE) – William Blair issued their Q1 2026 earnings per share estimates for uniQure in a research note issued on Thursday, February 27th. William Blair analyst S. Corwin expects that the biotechnology company will post earnings of ($1.39) per share for the quarter. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2026 earnings at ($1.41) EPS, Q3 2026 earnings at ($1.27) EPS and Q4 2026 earnings at ($1.22) EPS.

QURE has been the subject of a number of other research reports. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, February 5th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Wells Fargo & Company decreased their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Leerink Partners boosted their price target on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.89.

uniQure Trading Up 8.9 %

uniQure stock opened at $13.15 on Friday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a market capitalization of $640.73 million, a price-to-earnings ratio of -2.65 and a beta of 0.38. The stock has a 50-day moving average price of $15.05 and a 200 day moving average price of $9.81.

Institutional Trading of uniQure

Several large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC purchased a new stake in shares of uniQure during the fourth quarter worth approximately $38,410,000. Franklin Resources Inc. increased its position in shares of uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock worth $35,103,000 after purchasing an additional 494,726 shares in the last quarter. abrdn plc increased its position in shares of uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of uniQure by 81.3% during the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its position in shares of uniQure by 175.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after purchasing an additional 700,000 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,915 shares of company stock valued at $588,112 in the last three months. 4.74% of the stock is currently owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.